References
- Logan LK, Gandra S, Mandal S, et al. Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999–2012. J Pediatric Infect Dis Soc. 2017;6(4):352–359.
- Walters MS, Grass JE, Bulens SN, Hancock EB, et al. Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg Infect Dis. 2019;25(7):1281–1288.
- Savov E, Trifonova A, Kovachka K, et al. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa – a pilot Bulgarian study. Infect Dis (Lond). 2019;51(11-12):870–873.
- Sader HS, Castanheira M, Duncan LR, et al. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016. Diagn Microbiol Infect Dis. 2018;92(1):69–74.
- Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis. 2017;4(3):ofx176.
- Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301.
- Buehrle DJ, Shields RK, Clarke LG, et al. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother. 2017;61(1):e01243-16.
- Palavecino E, Ramirez K, Greene SR, et al. Co-existence of VIM-2-producing Pseudomonas aeruginosa and KPC-2 and OXA-232-co-producing Klebsiella pneumoniae in the United States. Ann Lab Med. 2020;40(3):267–269.
- Toleman MA, Rolston K, Jones RN, et al. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother. 2004;48(1):329–332.
- Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother. 2005;49(8):3538–3540.